BioMarin’s Pipeline Faces Skepticism As Analyst Questions Future Growth

BioMarin posts Q3 EPS of $0.91, nearly doubling last year’s $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.

Latest Ratings for BMRN

Date Firm Action From To
Feb 2022 Piper Sandler Maintains Overweight
Nov 2021 Credit Suisse Maintains Outperform
Nov 2021 Morgan Stanley Maintains Equal-Weight

View More Analyst Ratings for BMRN

View the Latest Analyst Ratings

read more

Leave a Reply

Your email address will not be published. Required fields are marked *